• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by scPharmaceuticals Inc. (Amendment)

    2/7/24 6:55:18 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPH alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    Amendment No. 2

     

    Under the Securities Exchange Act of 1934

     

      SCPHARMACEUTICALS INC.  
      (Name of Issuer)  
         
     

    Common Shares

     
      (Title of Class of Securities)  
         
      810648105  
      (CUSIP Number)  
         
      December 31, 2023  
      (Date of Event Which Requires Filing of this Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 810648105

     

    1.

    Names of Reporting Persons. AIGH Capital Management, LLC

    I.R.S. Identification Nos. of above persons (entities only).

     

    27-4413262

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship of Place of Organization

     

    Maryland

    Number of Shares

    Beneficially

    Owned by Each

    Reporting Person

    With

    5.

    Sole Voting Power

     

    3,106,795

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    3,106,795

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    3,106,795

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    8.7%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

     

     

     

    CUSIP No. 810648105

     

    1.

    Names of Reporting Persons. Orin Hirschman

    I.R.S. Identification Nos. of above persons (entities only).

     

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship of Place of Organization

     

    United States

    Number of Shares

    Beneficially

    Owned by Each

    Reporting Person

    With

    5.

    Sole Voting Power

     

    3,106,795

    6.

    Shared Voting Power

     

     

    7.

    Sole Dispositive Power

     

    3,106,795

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    3,106,795

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    8.7%

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

     

     

     

    ITEM 1:

     

    (a) Name of Issuer:

     

    scPharmaceuticals Inc.

     

    (b) Address of Issuer’s Principal Executive Offices:

     

    2400 District Avenue, Suite 3100, Burlington MA 01803

     

    ITEM 2:

     

    (a) Name of Person Filing:

     

    This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Act”):

     

      (i) AIGH Capital Management, LLC, a Maryland limited liability company (“AIGH LP”), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P. and WVP Emerging Manger Onshore Fund, LLC;
         
      (ii)

    AIGH Investment Partners, L.L.C., a Delaware limited liability company (“AIGH LLC”), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it;

         
      (iii) Mr. Orin Hirschman (“Mr. Hirschman”), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock indirectly held by AIGH LP, directly by AIGH LLC and Mr. Hirschman and his family directly.

     

    AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    (b) Address of Principal Business Office or, if None, Residence:

     

    The principal office and business address of AIGH Capital Management, LLC, AIGH Investment Partners, L.P., AIGH Investment Partners LLC, and Mr. Hirschman is:

     

    6006 Berkeley Avenue

    Baltimore MD 21209

     

    (c) Citizenship:

     

    See Item 2(a) above and Item 4 of each cover page.

     

    (d) Title of Class of Securities:

     

    Common Stock

     

    (e) CUSIP Number:

     

    810648105

     

     

     

     

    ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO §§240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
           
      (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
           

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________.

     

    ITEM 4: OWNERSHIP.

     

    See Item s 5,6,7,8 and 9 of each cover page.

     

    ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

     

    ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Not applicable.

     

    ITEM 7: IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    Not applicable.

     

    ITEM 8: IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not applicable.

     

    ITEM 9: NOTICE OF DISSOLUTION OF GROUP.

     

    Not applicable.

     

    ITEM 10: CERTIFICATIONS.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 7, 2024 By: /s/ Orin Hirschman
        Orin Hirschman,
        Individually and as (a) managing member of AIGH Capital Management LLC.: and (b) president of AIGH Investment Partners LLC.

     

     

    Get the next $SCPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCPH

    DatePrice TargetRatingAnalyst
    9/7/2023$20.00Buy
    Craig Hallum
    12/1/2022$25.00Outperform
    Cowen
    10/21/2022$14.00Buy
    Jefferies
    10/11/2022$11.00Mkt Perform → Outperform
    SVB Leerink
    8/2/2022$10.00Buy
    Maxim Group
    9/9/2021$6.00Market Perform
    SVB Leerink
    More analyst ratings

    $SCPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schaeffer Leonard D closing all direct ownership in the company (SEC Form 4)

    4 - scPharmaceuticals Inc. (0001604950) (Issuer)

    10/7/25 4:30:20 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO and Treasurer Nokes Rachael returned 125,675 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - scPharmaceuticals Inc. (0001604950) (Issuer)

    10/7/25 4:30:10 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Baylor-Henry Minnie

    4 - scPharmaceuticals Inc. (0001604950) (Issuer)

    10/7/25 4:30:13 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

    Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals' 90 trading day VWAP, and total consideration of up to $6.35 per share represents up to a 31% premium to scPharmaceuticals' closing price on August 22, 2025Strengthens organization by integrating scPharmaceuticals

    8/25/25 7:30:00 AM ET
    $MNKD
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111

    BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111 formulation is the subject of a supplemental NDA expected to be filed by the Company this quarter. The five patents, once issued, will join four additional patents owned by the Company that cover the SCP-111 formulation. "These allowances are vital developments

    8/14/25 8:30:46 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

    Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $40.8 million as of June 30, 2025 Investor conference call and webcast today, Thursday, August 7th, at 4:30pm ET BURLINGTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat

    8/7/25 4:01:50 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FUROSCIX issued to SCPHARMACEUTICALS INC

    Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form

    10/11/22 1:54:57 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Orbimed Advisors Llc bought $2,000,000 worth of shares (500,000 units at $4.00) (SEC Form 4)

    4 - scPharmaceuticals Inc. (0001604950) (Issuer)

    8/15/24 4:51:14 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    SEC Filings

    View All

    SEC Form EFFECT filed by scPharmaceuticals Inc.

    EFFECT - scPharmaceuticals Inc. (0001604950) (Filer)

    11/20/25 12:15:13 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by scPharmaceuticals Inc.

    EFFECT - scPharmaceuticals Inc. (0001604950) (Filer)

    11/20/25 12:15:07 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by scPharmaceuticals Inc.

    EFFECT - scPharmaceuticals Inc. (0001604950) (Filer)

    11/20/25 12:15:09 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on scPharmaceuticals with a new price target

    Craig Hallum initiated coverage of scPharmaceuticals with a rating of Buy and set a new price target of $20.00

    9/7/23 9:06:27 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cowen initiated coverage on scPharmaceuticals with a new price target

    Cowen initiated coverage of scPharmaceuticals with a rating of Outperform and set a new price target of $25.00

    12/1/22 7:54:00 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on scPharmaceuticals with a new price target

    Jefferies resumed coverage of scPharmaceuticals with a rating of Buy and set a new price target of $14.00

    10/21/22 7:40:23 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    Leadership Updates

    Live Leadership Updates

    View All

    Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

    NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

    3/1/22 4:05:00 PM ET
    $APYX
    $LNTH
    $PRTK
    Medical/Dental Instruments
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Biotechnology: Pharmaceutical Preparations

    $SCPH
    Financials

    Live finance-specific insights

    View All

    MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

    Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals' 90 trading day VWAP, and total consideration of up to $6.35 per share represents up to a 31% premium to scPharmaceuticals' closing price on August 22, 2025Strengthens organization by integrating scPharmaceuticals

    8/25/25 7:30:00 AM ET
    $MNKD
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

    Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $40.8 million as of June 30, 2025 Investor conference call and webcast today, Thursday, August 7th, at 4:30pm ET BURLINGTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat

    8/7/25 4:01:50 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

    BURLINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 7, 2025, to discuss the financial results for the second quarter 2025 and provide a business update. A link to the live webcast can be found here. Participants should dial (800) 715-9871 (toll-free) or (646) 307-1963 (toll) and use the passcode 4965353 The live webcast and replay of the conference call can be accessed here or under "News & Events" in the I

    7/31/25 4:01:00 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

    SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

    11/15/24 4:06:50 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

    SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

    11/14/24 5:48:35 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

    SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

    11/14/24 3:58:44 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care